Mental deterioration
Alzheon Investigates Subgroup Data Following Phase 3 Trial of ALZ-801 in Alzheimer’s Disease
Alzheimer’s disease , ALZ-801 , Valiltramiprosate , APOE4 genotype , Mild cognitive impairment (MCI) , Amyloid-targeting therapy , Phase 3 trial results , Cognitive decline , Subgroup analysis , Precision medicine
FDA Approves Monthly Maintenance Dosing for Eisai and Biogen’s Alzheimer’s Drug Leqembi
Leqembi, Alzheimer’s disease, FDA approval, monthly maintenance dosing, Eisai, Biogen, amyloid-beta, cognitive decline
Eisai’s Alzheimer’s Drug Leqembi Shows Long-Term Benefits, Despite Study Limitations
Eisai, Leqembi, Alzheimer’s drug, long-term benefits, study limitations, cognitive decline, amyloid plaques, Biogen
Novo’s GLP-1 Liraglutide May Protect Brain from Alzheimer’s, New Study Finds
GLP-1, Liraglutide, Alzheimer’s Disease, Brain Protection, Cognitive Decline, Novo Nordisk
Anavex’s New Analysis of Alzheimer’s Pill Shows Mixed Results
Anavex, Alzheimer’s disease, blarcamesine, Phase IIb/III trial, clinical efficacy, neurodegeneration, cognitive decline, amyloid-beta, brain atrophy, EMA approval.
FDA Approves Eli Lilly’s Alzheimer’s Drug Donanemab, Offering New Treatment Option
Alzheimer’s disease, Eli Lilly, FDA approval, donanemab, Kisunla, anti-amyloid monoclonal antibody, cognitive decline, amyloid plaques, treatment options